Immunocore

News

ESMO: J&J’s Tagrisso challenge, and other highlights

With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.

News

Immunocore gets EU nod for TCR cancer therapy Kimmtrak

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the Europea

News

Immunocore claims first-ever FDA approval for TCR cancer the...

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology.

News

Ex-Roche, Novartis, AstraZeneca leaders appointed to biotech...

Three more big pharma R&D names have made the jump to biotech as Voyager Therapeutics, ImmunSYS and Immunocore announce they have appointed former execs from Roche, Novartis and AstraZe

News

Immunocore’s rare cancer treatment gains UK Promising Medici...

Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.

News